Filter by: patients
What is Everolimus?

Everolimus is an antineoplastic agent used in the treatment of advanced renal cell cancer, after not having therapeutic response with sunitinib or sorafenib. Off label it is used as an immunosuppressant following solid organ transplant.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Transplant rejection prevention 1 0
Pancreatic Neuroendocrine Tumor 1 0
Kidney Transplant 1 1 Efficacy_cant_tell
Heart Transplant 1 1 Efficacy_major

See all 7 patients currently taking Everolimus

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
1
Moderate
0
Mild
0
None
1

Reported Dosages

  0.75 mg daily 1 mg daily 1.5 mg daily 3 mg daily 5 mg daily 20 mg daily 100 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Everolimus (multiple reasons could be selected)
Reason # Patients Percentage of patients
Side effects too severe 1   Side effects too severe: 50%
Other 1   Other: 50%

See all 2 patients who’ve stopped taking Everolimus

Currently Taking Everolimus

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Everolimus

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Everolimus

Always
2 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Burden of Everolimus

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
2 100%

Cost

Paid out of pocket

Cost of Everolimus

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
1 100%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 23, 2012.